The European Commission has approved Saria’s acquisition of sole control over Quintet and Bioiberica, as well as its acquisition of joint control over Teeuwissen and Jagero II. Saria manufactures products using animal and vegetable by-products. Teeuwissen and Jagero II are holding companies involved in commercializing meat for human consumption.
The acquisitions of Teeuwissen and Jagero II create horizontal overlaps in the market for animal by-products in the United Kingdom and France. Yet the Commission found that other competitors, including overseas suppliers, and slaughterhouses pose enough competition so that Saria would not be able to increase prices as a result of the merger.
Source: EC Press Release
Related content: Reform of the EU Merger Regulation: Looking Out for the Minority (Christian Riis-Madsen, Sophia Stephanou & Killian Kehoe, O’Melveny & Myers)
Featured News
House Budget Bill’s Moratorium on State AI Laws Could Undo A Range of Tech Regs, Critics Say
May 14, 2025 by
CPI
Microsoft Nears EU Antitrust Resolution Over Teams Bundling, Sources Say
May 14, 2025 by
CPI
CMA Investigates Aviva’s £3.6B Acquisition of Direct Line Group
May 14, 2025 by
CPI
Google Urges Texas Judge to Disregard Virginia Antitrust Ruling
May 14, 2025 by
CPI
Anthropic Ordered to Respond After AI Allegedly Fabricates Citation in Legal Filing
May 14, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas